Margaret Whitacre

1.7k total citations
35 papers, 1.3k citations indexed

About

Margaret Whitacre is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Margaret Whitacre has authored 35 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Epidemiology and 9 papers in Molecular Biology. Recurrent topics in Margaret Whitacre's work include Lung Cancer Research Studies (12 papers), Neuroendocrine Tumor Research Advances (11 papers) and Cancer therapeutics and mechanisms (7 papers). Margaret Whitacre is often cited by papers focused on Lung Cancer Research Studies (12 papers), Neuroendocrine Tumor Research Advances (11 papers) and Cancer therapeutics and mechanisms (7 papers). Margaret Whitacre collaborates with scholars based in United States, Netherlands and Malaysia. Margaret Whitacre's co-authors include Joseph Aisner, David A. Van Echo, Merrill J. Egorin, Eve A. Olman, Bruce Thompson, Alan Forrest, Stuart J. Tipping, Wiernik Ph, Van Echo Da and Peter H. Wiernik and has published in prestigious journals such as The Journal of Immunology, Cancer and Frontiers in Immunology.

In The Last Decade

Margaret Whitacre

34 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margaret Whitacre United States 20 743 360 337 334 270 35 1.3k
Antonio Brugarolas Spain 18 700 0.9× 294 0.8× 151 0.4× 403 1.2× 138 0.5× 79 1.3k
Po‐Min Chen Taiwan 23 705 0.9× 500 1.4× 252 0.7× 243 0.7× 225 0.8× 87 1.9k
B L Lum United States 21 1.1k 1.5× 565 1.6× 148 0.4× 259 0.8× 95 0.4× 33 1.9k
John R. Murren United States 22 998 1.3× 520 1.4× 308 0.9× 567 1.7× 270 1.0× 65 1.9k
Takao Ohnuma United States 22 462 0.6× 592 1.6× 103 0.3× 174 0.5× 121 0.4× 81 1.5k
Salvatore Pisconti Italy 22 692 0.9× 502 1.4× 150 0.4× 434 1.3× 154 0.6× 97 1.7k
Νicolas Tsavaris Greece 22 999 1.3× 259 0.7× 170 0.5× 495 1.5× 161 0.6× 87 1.7k
Stefanie Hammer Germany 23 545 0.7× 835 2.3× 407 1.2× 322 1.0× 84 0.3× 63 2.1k
Kiyoji Kimura Japan 16 452 0.6× 287 0.8× 69 0.2× 231 0.7× 136 0.5× 78 1.1k
Eros Ferrazzí Italy 18 455 0.6× 861 2.4× 135 0.4× 155 0.5× 154 0.6× 48 1.8k

Countries citing papers authored by Margaret Whitacre

Since Specialization
Citations

This map shows the geographic impact of Margaret Whitacre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Whitacre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Whitacre more than expected).

Fields of papers citing papers by Margaret Whitacre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Whitacre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Whitacre. The network helps show where Margaret Whitacre may publish in the future.

Co-authorship network of co-authors of Margaret Whitacre

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Whitacre. A scholar is included among the top collaborators of Margaret Whitacre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Whitacre. Margaret Whitacre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Miller, Shannon M., et al.. (2020). A novel TLR adjuvant increases the efficacy of vaccines against fentanyl-induced toxicity and overdose. The Journal of Immunology. 204(1_Supplement). 91.25–91.25. 1 indexed citations
3.
Miller, Shannon M., Margaret Whitacre, Mark T. Livesay, et al.. (2020). Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice. Frontiers in Immunology. 11. 406–406. 40 indexed citations
4.
Smith, Alyson, Shannon M. Miller, Robert Child, et al.. (2019). Species-Specific Structural Requirements of Alpha-Branched Trehalose Diester Mincle Agonists. Frontiers in Immunology. 10. 338–338. 21 indexed citations
5.
Srivastava, Shivani, David Y. Lewis, Zdenka Hašková, et al.. (2013). Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunology Immunotherapy. 62(6). 1073–1082. 55 indexed citations
6.
Conley, Barbara A., et al.. (1993). Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemotherapy and Pharmacology. 33(2). 107–112. 38 indexed citations
7.
Aisner, Joseph, Margaret Whitacre, Daniel R. Budman, et al.. (1992). Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 29(6). 435–438. 14 indexed citations
8.
Melink, Teresa J. & Margaret Whitacre. (1991). Planning and implementing clinical trials. Seminars in Oncology Nursing. 7(4). 243–251. 11 indexed citations
9.
Egorin, Merrill J., et al.. (1987). Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.. PubMed. 47(2). 617–23. 68 indexed citations
10.
Poplin, Elizabeth, et al.. (1987). Small cell carcinoma of the lung: Influence of age on treatment outcome. Lung Cancer. 3(3-4). 143–143. 47 indexed citations
11.
Egorin, Merrill J., David A. Van Echo, Margaret Whitacre, et al.. (1986). Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.. PubMed. 46(3). 1513–20. 52 indexed citations
12.
Aisner, Joseph, Margaret Whitacre, Jeffrey S. Abrams, & Kathleen J. Propert. (1986). Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung.. PubMed. 13(3 Suppl 3). 54–62. 22 indexed citations
13.
Echo, David A. Van, et al.. (1986). Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.. PubMed. 70(6). 721–5. 7 indexed citations
14.
Egorin, Merrill J., David A. Van Echo, Margaret Whitacre, et al.. (1985). Human Pharmacokinetics and Correlation With Clinical Toxicities of the Anthracycline Antibiotic Menogaril (7-Omen). Journal of Bioresource Management. 26. 155. 3 indexed citations
15.
Hamilton, B P, et al.. (1984). Serum thyroid hormone changes during whole body hyperthermia. Cancer. 54(11). 2432–2435. 9 indexed citations
16.
Aisner, Joseph, et al.. (1982). Lung cancer as a complication of prolonged survival in patients with lymphoma. Medical and Pediatric Oncology. 10(4). 331–338. 16 indexed citations
17.
Aisner, Joseph, David A. Van Echo, Margaret Whitacre, & Peter H. Wiernik. (1982). A phase I trial of continuous infusion VP16-213 (Etoposide). Cancer Chemotherapy and Pharmacology. 7(2-3). 157–160. 36 indexed citations
18.
Egorin, Merrill J., et al.. (1982). Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer Chemotherapy and Pharmacology. 8(1). 41–46. 11 indexed citations
19.
Bachur, Nicholas R., Jerry M. Collins, James A. Kelley, et al.. (1982). Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics. Clinical Pharmacology & Therapeutics. 31(5). 650–655. 21 indexed citations
20.
Ostrow, S., et al.. (1981). Physiologic response and toxicity in patients undergoing whole-body hyperthermia for the treatment of cancer.. PubMed. 65(3-4). 323–5. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Brugarolas Breakdown of academic impact, for papers by Po‐Min Chen Breakdown of academic impact, for papers by B L Lum Breakdown of academic impact, for papers by John R. Murren Breakdown of academic impact, for papers by Takao Ohnuma Breakdown of academic impact, for papers by Salvatore Pisconti Breakdown of academic impact, for papers by Νicolas Tsavaris Breakdown of academic impact, for papers by Stefanie Hammer Breakdown of academic impact, for papers by Kiyoji Kimura Breakdown of academic impact, for papers by Eros Ferrazzí
Rankless by CCL
2026